ArticleACS omega2025
Discovery and Exploration of Small Molecule Binders for CT83: Computational Insights from Homology Modeling, Virtual Screening, MD Simulations, Interaction Fingerprint, and Network Communications.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interconversion of the (+)-O-desmethyltramadol to the lowest-energy conformer when coupled to µ-opioid receptor: comprehensive analysis using in silico molecular modeling.Journal of computer-aided molecular design · 2025Article
- Matrix Metalloproteinase-2-Responsive Peptide-Modified Cleavable PEGylated Liposomes for Paclitaxel Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kita-Kyushu lung cancer antigen-1 (KK-LC-1), also known as CT83, is a member of the cancer/testis antigen (CTA) family and has emerged as an important target for cancer therapy. Its expression is typically restricted to certain cancers, including nonsmall cell lung cancer, gastric cancer, triple-negative breast cancer, and testicular tissues, making it an attractive candidate for targeted drug development against cancer cells. We identified several new small molecules using PubChem chemical property searches, Lipinski rule-based filtration, virtual screening, molecular docking, and molecular dynamics (MD) simulations, with reference to the compound Z839878730 reported in the literature. The selected molecules were CID24326943, CID24459131, CID46375999, CID46533890, and CID55836895. MD simulations (200 ns) revealed stable CT83-ligand complexes, with MMPBSA calculations showing that Z839878730, CID24459131, and CID46375999 exhibited the most favorable relative binding free energies. Among these, CID46375999 shared greater similarity with the reference compound, featuring a 1,3,4-thiadiazole-2-carboxamide scaffold, hydrophobic properties, and hydrogen bonding potential. In contrast, CID24459131, which features an imidazolidinone ring and relatively bulky substituents such as a diphenylethyl moiety, exhibits a more flexible and extended conformation. Although CID46375999 contains a piperidine ring, its overall structure is more conformationally constrained compared to CID24459131, likely due to fewer rotatable bonds and a more compact architecture. Overall, CID46375999 aligned more closely with the reference compound in terms of chemical properties. Interaction fingerprint analysis revealed frequent interactions with key residues Leu15, Ile16, Phe18, Trp19, Arg22, Leu38, Arg42, Pro43, Arg76, Gln77, and Ile80, including hydrophobic interactions, π-stacking (Phe18 and Trp19), and H-bonds (Arg22, Arg76, Gln77, and Ser44), and the communication network of these interactions provided insights into binding dynamics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.